Modality
Multispecific
MOA
PCSK9i
Target
SHP2
Pathway
PD-1/PD-L1
DMDRSV
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Jan 2031
Phase 2Current
NCT03049702
773 pts·DMD
2023-02→2031-01·Not yet recruiting
NCT06951144
1,614 pts·RSV
2025-10→2026-04·Terminated
2,387 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-033d awayPh3 Readout· RSV
2031-01-244.8y awayPh3 Readout· DMD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2026-04-03 · 3d away
RSV
Ph3 Readout
2031-01-24 · 4.8y away
DMD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03049702 | Phase 2/3 | DMD | Not yet recr... | 773 | CfB |
| NCT06951144 | Phase 2/3 | RSV | Terminated | 1614 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |